RPAY vs. PHR, PSFE, ADV, TTGT, MAX, CNDT, RDWR, VVI, IMXI, and ACCD
Should you be buying Repay stock or one of its competitors? The main competitors of Repay include Phreesia (PHR), Paysafe (PSFE), Advantage Solutions (ADV), TechTarget (TTGT), MediaAlpha (MAX), Conduent (CNDT), Radware (RDWR), Viad (VVI), International Money Express (IMXI), and Accolade (ACCD).
Phreesia (NYSE:PHR) and Repay (NASDAQ:RPAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings.
92.1% of Phreesia shares are held by institutional investors. Comparatively, 82.7% of Repay shares are held by institutional investors. 5.8% of Phreesia shares are held by insiders. Comparatively, 11.0% of Repay shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Phreesia has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Repay has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Phreesia currently has a consensus target price of $31.62, indicating a potential upside of 42.54%. Repay has a consensus target price of $10.50, indicating a potential upside of 0.10%. Given Repay's stronger consensus rating and higher probable upside, research analysts clearly believe Phreesia is more favorable than Repay.
In the previous week, Repay had 18 more articles in the media than Phreesia. MarketBeat recorded 20 mentions for Repay and 2 mentions for Phreesia. Repay's average media sentiment score of 1.28 beat Phreesia's score of 0.78 indicating that Phreesia is being referred to more favorably in the media.
Repay has a net margin of -29.49% compared to Repay's net margin of -38.42%. Phreesia's return on equity of 7.74% beat Repay's return on equity.
Repay has lower revenue, but higher earnings than Phreesia. Repay is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.
Phreesia received 30 more outperform votes than Repay when rated by MarketBeat users. Likewise, 64.74% of users gave Phreesia an outperform vote while only 61.18% of users gave Repay an outperform vote.
Summary
Phreesia and Repay tied by winning 9 of the 18 factors compared between the two stocks.
Get Repay News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
